Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Final Glance: Biotechnology companies
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
FDA reviewing what could be first biosimilar drug
AP - Thu Jul 24, 4:33PM CDT
WASHINGTON, D.C. (AP) — The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.
Amgen Announces Webcast of 2014 Second Quarter Financial Results
PR Newswire - Thu Jul 24, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Surveyed U.S. and EU5 Dermatologists Indicate that Short-Term and Long-Term Effects on Psoriatic Plaque Clearance are Two Attributes that Most Strongly Influence Prescribing Decisions in Moderate to Severe Psoriasis
PR Newswire - Thu Jul 24, 1:00PM CDT
Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis. Emerging therapies that offer improved effect in these attributes over current therapies would be well received and poised for strong uptake. Based on thought leaders' opinions and clinical trial data, emerging therapies, especially IL-17 inhibitors (Novartis's secukinumab, Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab, Eli Lilly's ixekizumab) have potential, owing to their improved efficacy relative to current therapies in improving psoriatic plaques. However, based on currently available data and physicians' opinions, emerging therapies lack the efficacy, safety and tolerability, and/or delivery features that would allow them to offer better overall clinical profiles than that of Janssen's Stelara.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Midday Glance: Biotechnology companies
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Jul 24, 10:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen
PR Newswire - Thu Jul 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Amgen (Nasdaq:AMGN-Free Report), InterMune (Nasdaq:ITMN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.